In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeuroDerm Ltd.

Division of Mitsubishi Chemical Holdings Corp.
www.neuroderm.com

Latest From NeuroDerm Ltd.

Spotlight On Israel: Accessing Private Cash For Novel Technologies

Israel's appetite for biopharma investment is growing, but competition for cash is still tough and local investors are not only looking at regional startups to place their bets on.

Israel Business Strategies

Market Intel: Pain Is Biggest Market For Transdermal Drug Delivery But Not A Patch Over Neuro For Growth

The growing aging population and rising obesity rates are paving the way for patch-based drug delivery systems to treat such common age-related diseases as Alzheimer's and Parkinson's, hormonal deficiencies, heart disease, as well as for managing acute and chronic pain patients. According to a new report by Meddevicetracker, the global market for transdermal patch products will reach $8.1bn by 2021, a CAGR of 2.9% from 2016. In this feature, we'll take a closer look at the overall market and the key players in the individual segments in this overall market. We'll take a deep dive into the neurological disorders segment, which is expected to see the biggest growth in the overall segment. We'll also feature physician specialty surveys outlining the pros and cons of using patch-based systems.

Combination Products Market Intelligence

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals

Acorda Enacts 'Poison Pill' In Effort To Stave Off Scopia

After the hedge fund Scopia called on Acorda to investigate the possibility of a sale, the biotech's argument for its current direction faltered due to an FDA refuse-to-file letter for Inbrija. Acorda then adopted a shareholder rights plan to buy time.

Business Strategies M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Transdermal
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Mitsubishi Chemical Holdings Corp.
  • Senior Management
  • Oded S Lieberman, PhD, CEO
    Oron Yacoby-Zeevi, PhD, VP, R&D
    Roy Golan, VP, Fin.
    Revital Mandil-Levin, Head, BD
    Tami Yardeni, COO
    Eran Shor, VP, Devices
  • Contact Info
  • NeuroDerm Ltd.
    Phone: (972) 8-9462729
    3 Pekeris St., Ruhrberg Science Bldg.
    Rabin Science
    Rehovot, 7670212
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register